Recent advancements in cell-based therapies highlight the potential of mesenchymal stromal cells (MSCs) to address various medical challenges. Equine cord blood-derived MSCs (eCB-MSCs), known for their regenerative and immunomodulatory abilities, are particularly promising for veterinary applications. Efficient expansion of these cells is crucial to meet therapeutic demands, a task not adequately met by traditional static [...]
A new study introduces an advanced approach for dental tissue regeneration using an injectable microcarrier-hydrogel composite system. This method aims to address the limitations of conventional stem cell therapies, particularly the challenges of low cell viability and poor integration after transplantation. By combining dental pulp stem cells (DPSCs) with a composite of gelatin methacrylate (GelMA) [...]
In partnership with UNSW, we are excited to offer a fully funded PhD position focused on developing animal-free hydrogels for organoid culture and drug screening. This multidisciplinary project integrates biochemistry and cell biology to create innovative synthetic and natural polymer hydrogels, contributing to advancements in regenerative medicine and pharmacology. Project Overview The PhD candidate [...]
In a recent publication, researchers have made significant advancements in the scalable production of viral vectors for SARS-CoV-2 vaccines. By leveraging microcarrier-based cell culture in stirred-tank bioreactors, this method offers an efficient and cost-effective solution for lab-based vaccine production. These innovations are essential for addressing the urgent need for rapid vaccine development, particularly during global [...]
One of the most significant advancements in drug discovery is the ability to screen bioactive compounds effectively and at scale. This is particularly important when using cells like HEK293T cells, which are difficult to produce at scale. A recent study published in the Journal of Pharmaceutical and Biomedical Analysis demonstrates how microcarrier culture can [...]
In a recent study, researchers have developed a novel microcarrier-microbioreactor platform that shows significant promise for improving the manufacturing process of mesenchymal stem and stromal cells (MSCs), which are vital for treating a range of clinical conditions. Despite the potential of MSCs, their clinical application has been hindered by challenges in achieving consistent product [...]
A recent study has shed light on a novel process intensification strategy for the expansion of human induced pluripotent stem cells (hiPSCs), which holds promise for enhancing the manufacturing of hiPSC-based therapeutics. The research focused on evaluating a one-step inoculation (OSI) approach, commonly used in antibody and vaccine production, and its potential application to [...]
Wharton’s jelly mesenchymal stem/stromal cells (WJMSCs) have gained significant attention due to their potential in immunomodulatory, anti-inflammatory, tissue repair, and regenerative therapies. These cells have shown promise in treating various clinical conditions, highlighting the need for scalable manufacturing processes to meet commercial and clinical demands. Recent research has focused on developing a robust, scalable, and [...]
We are excited to announce that our Chief Scientific Advisor, Prof. Steve Oh, PhD, will be chairing an insightful webinar on "Bioprocessing and Artificial Intelligence in Cell Therapies: China’s Model." This event is presented by the ISCT Asia Regional Executive Committee and sponsored by REGEN-αGEEK (Haining) Biotechnology Co., Ltd. Event Details: Date: Wednesday, August 7, [...]
Influenza viruses pose a significant threat to global health, with the potential to trigger pandemics. Vaccination remains the primary strategy to reduce illness and death during such outbreaks. Addressing the urgent need for readily available vaccines, a new study introduces an advanced manufacturing process for inactivated influenza H5N1 vaccines. This innovative process leverages Madin-Darby canine [...]
